3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
3
Thoracic
1
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Breast Neoplasms
22
Melanoma
8
Triple Negative Breast Neoplasms
7
Neoplasm Metastasis
7
Carcinoma, Non-Small-Cell Lung
7
Ovarian Neoplasms
6
Colorectal Neoplasms
6
Uterine Cervical Neoplasms
3
Neoplasms
3
Carcinoma, Renal Cell
3
Carcinoma, Merkel Cell
3
Carcinoma, Hepatocellular
3
Breast Neoplasms, Male
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Skin Neoplasms
2
Sarcoma
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Lymphoma
2
Head and Neck Neoplasms
2
Fallopian Tube Neoplasms
2
Carcinoma, Transitional Cell
2
Uveal Melanoma
1
Turcot syndrome
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma, Synovial
1
Recurrence
1
Rectal Neoplasms
1
Interventions
pembrolizumab
3
fludarabine
2
Paclitaxel
2
Gemcitabine
2
Cyclophosphamide
2
Azacitidine
2
vocimagene amiretrorepvec
1
temsirolimus
1
spartalizumab
1
sonidegib
1
sacituzumab govitecan
1
ruxolitinib
1
rucaparib
1
ridaforolimus
1
pazopanib
1
motexafin gadolinium
1
lenvatinib
1
durvalumab
1
depatuxizumab mafodotin
1
cediranib
1
cc-486
1
carboxyamido-triazole
1
abiraterone
1
Thalidomide
1
Temozolomide
1
Sorafenib
1
Sirolimus
1
Radiation
1
Quality of Life
1
Proton Pump Inhibitors
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioblastoma
×
Interleukin-2
×
Breast
×
Clear all
NCT07410494
2026-02-18
SELECT-CAR-NK
Essen Biotech
Phase 1/2
Recruiting
85 enrolled